The Gulf Time Newspaper One of the finest business newspapers in the UAE brought to you by our professional writers and editors.
Bloomberg
GSK Plc and CureVac NV are planning further patient trials of their messenger RNA vaccines for flu and Covid-19 after promising early results, though the partners still lag behind rivals in the race to expand use of mRNA technology.
The partners’ second-generation vaccine candidates showed promising abilities to spur the immune system in early-stage trials, CureVac said. The companies plan to start a mid-stage trial of the Covid vaccine around mid-year, targeting the most relevant variant, while a seasonal flu study to target four different strains should begin in the first half, CureVac said.
The results will enable CureVac to “turn the page and enter 2023 as a competitive player in the development of mRNA therapies,†Chief Executive Officer Franz-Werner Haas said in a statement.
CureVac shares rose as much as 24% in pre-market trading in New York. GSK shares were little changed in London.
Despite being one of the first companies to start work on mRNA vaccines, CureVac fell behind rivals BioNTech SE and Moderna Inc.